[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624668":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":42,"responsibleParty":76,"collaborators":80,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":26,"enrollmentInfo":94,"targetDuration":26,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":106,"whyStopped":26,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Ascension Health","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active Treatment Arm","ACTIVE_COMPARATOR","Heart Logic threshold set to 10 (from 16) will trigger a treatment algorithm, which includes up titration of GDMT",[13],"Device: Heartlogic Diagnostic Tool Threshold Change",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Arm","PLACEBO_COMPARATOR","Heart Logic transmission of 16 or greater may be reported to the appropriate device clinic staff by Latitude transmission and then referred to the appropriate treating provider. Medication changes will be based upon physician preference\u002Fstandards. Repeat transmissions, follow-up, laboratory studies will be per physician preference.",[19],"Device: Heartlogic Diagnostic Tool Unchanged Threshold",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Heartlogic Diagnostic Tool Threshold Change","Heart Logic threshold set to 10 (from 16)",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Heartlogic Diagnostic Tool Unchanged Threshold","Heartlogic Threshold to remain at 16, which is the normal limit.",[15],[32],{"name":33,"affiliation":5,"role":34},"Robert Pickett, MD","PRINCIPAL_INVESTIGATOR",[36,40],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","615-329-5144","robert.pickett@ascension.org",{"name":41,"role":37,"phone":38,"phoneExt":26,"email":26},"Saint Thomas Heart at Saint Thomas Midtown",[43,63],{"facility":44,"status":26,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Ascension St. Vincent Medical Group","Indianapolis","Indiana","46260","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-86.15804,39.76838,{"lat":54,"lon":53},[57,61,62],{"name":58,"role":37,"phone":59,"phoneExt":26,"email":60},"Jasen Gilge, MD","317-338-6666","Jasen.gilge@ascension.org",{"name":44,"role":37,"phone":59,"phoneExt":26,"email":26},{"name":58,"role":34,"phone":26,"phoneExt":26,"email":26},{"facility":41,"status":26,"city":64,"state":65,"zip":66,"country":48,"countryCode":49,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Nashville","Tennessee","37203",{"type":51,"coordinates":68},[69,70],-86.78444,36.16589,{"lat":70,"lon":69},[73,74,75],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},{"name":41,"role":37,"phone":38,"phoneExt":26,"email":26},{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":77,"investigatorFullName":78,"investigatorTitle":79,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Robert Pickett","MD",[81,83],{"name":82,"class":6},"Boston Scientific Corporation",{"name":5,"class":6},"100624668","evaluation-of-the-heartlogic-diagnostic-in-optimizing-guideline-directed-medical-therapy-in-patients-with-congestive-heart-failure-and-chronically-low-ejection-fractions-efs-100624668",false,"NCT07412626","Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)","HeartLogic Optimization of CHF Medications in Chronic Low EF Population: A Follow-on Study","Heartlogic ISR","Inclusion Criteria:\n\n* Age 18 years or older\n* EF \\\u003C\u002F=35%\n* Prior hospitalization within the last two years or prior decompensation to NYHA class III or IV over the last 12 months that was treated without hospitalization\n* HeartLogic capable ICD or CRT-D (Patients with HeartLogic capable ICD or CRT-D can be enrolled at time of de novo implantation or generator change out or at the time of the 2 week wound check. Prior Heart logic capable ICF or CRT-D implants can be enrolled if heart failure hospitalization shows decompensation within six months (prior implants must have at least 1 year battery life)\n\nExclusion Criteria:\n\n* Refuse to give consent\n* Have Life expectancy of less than one-year\n* Documented noncompliance that limits medication use\n* Patients on Dialysis (renal insufficiency but not on dialysis is NOT an exclusion)\n* Pregnancy","ALL","18 Years",{"count":95,"type":96},135,"ESTIMATED","INTERVENTIONAL",[99],"NA","The goal of this trial is to determine if the addition of the Heart Logic diagnostic alerts to standard of care therapies will lessen hospitalizations and improve quality of life in patients with heart failure.",[102,103],"Congestive Heart Failure Chronic","Low Ejection Fraction",[105],"Heart Failure","NOT_YET_RECRUITING","2026-02-13",{"date":109,"type":110},"2026-02-17","ACTUAL",{"date":112,"type":96},"2026-04-01",{"date":114,"type":96},"2028-03",{"name":78,"class":6},2]